

Transient Shielding of Intimin and the Type III Secretion System of Enterohemorrhagic and Enteropathogenic *Escherichia coli* by a Group 4 Capsule^{∇†}

Yulia Shifrin,¹ Adi Peleg,¹ Ophir Ilan,¹ Chen Nadler,¹ Simi Kobi,¹ Kobi Baruch,¹ Gal Yerushalmi,¹ Tatiana Berdichevsky,¹ Shoshy Altuvia,¹ Maya Elgrably-Weiss,¹ Cecilia Abe,^{2‡} Stuart Knutton,² Chihiro Sasakawa,³ Jennifer M. Ritchie,⁴ Matthew K. Waldor,⁴ and Ilan Rosenshine^{1*}

Department of Molecular Genetics and Biotechnology, The Hebrew University Faculty of Medicine, POB 12272, Jerusalem 91120, Israel¹; Institute of Child Health, University of Birmingham, Whittall Street, Birmingham B4 6NH, United Kingdom²; Departments of Microbiology and Immunology and Infectious Disease Control, International Research Center for Infectious Disease, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan³; and The Channing Laboratory, Harvard Medical School, 181 Longwood Ave., Boston Massachusetts 02115⁴

Received 31 March 2008/Accepted 12 May 2008

Enterohemorrhagic and enteropathogenic *Escherichia coli* (EHEC and EPEC, respectively) strains represent a major global health problem. Their virulence is mediated by the concerted activity of an array of virulence factors including toxins, a type III protein secretion system (TTSS), pili, and others. We previously showed that EPEC O127 forms a group 4 capsule (G4C), and in this report we show that EHEC O157 also produces a G4C, whose assembly is dependent on the *etp*, *etk*, and *wzy* genes. We further show that at early time points postinfection, these G4Cs appear to mask surface structures including intimin and the TTSS. This masking inhibited the attachment of EPEC and EHEC to tissue-cultured epithelial cells, diminished their capacity to induce the formation of actin pedestals, and attenuated TTSS-mediated protein translocation into host cells. Importantly, we found that Ler, a positive regulator of intimin and TTSS genes, represses the expression of the capsule-related genes, including *etp* and *etk*. Thus, the expression of TTSS and G4C is conversely regulated and capsule production is diminished upon TTSS expression. Indeed, at later time points postinfection, the diminishing capsule no longer interferes with the activities of intimin and the TTSS. Notably, by using the rabbit infant model, we found that the EHEC G4C is required for efficient colonization of the rabbit large intestine. Taken together, our results suggest that temporal expression of the capsule, which is coordinated with that of the TTSS, is required for optimal EHEC colonization of the host intestine.

Enterohemorrhagic *Escherichia coli* (EHEC) is an emerging pathogen causing outbreaks of food-borne gastroenteritis manifested by bloody diarrhea, which may progress to the potentially fatal hemolytic-uremic syndrome. The latter involves severe complications, such as renal impairment, hypertension, and central nervous system manifestations mainly caused by SLT toxins (3, 22). EHEC belongs to the family of the attaching and effacing (AE)-inducing pathogens, which includes the closely related species enteropathogenic *E. coli* (EPEC), *Citrobacter rodentium*, and rabbit EPEC. When colonizing the gut, these pathogens form AE lesions on the intestinal epithelial cell surface. AE lesions are characterized by localized destruction of the brush border microvilli, intimate bacterial attachment to host cells, and the formation of actin structures, termed pedestals, beneath the attached bacteria (24). This histopathology is dependent upon a type III protein

secretion system (TTSS), which functions as a molecular syringe to translocate effector proteins from the bacterial cytoplasm directly into the cytoplasm of host epithelial cells (15). These effectors subvert normal host cell functions and are required for efficient host colonization (15, 34, 35). One of these effectors, Tir, is inserted into the host cell membrane to form a binding site for an outer membrane adhesin, intimin. Interaction of intimin with translocated Tir promotes tight bacterial attachment to the host cell and is essential for the formation of actin pedestals (15).

The TTSS and related proteins are encoded by 41 genes organized in several operons (operons *LEE1* to *LEE5*) clustered in the locus of enterocyte effacement (LEE) (15). Alongside the TTSS and its effectors, EHEC and EPEC encode an array of additional confirmed and putative virulence factors including the Shiga toxins, EspP, Efa1, and others (11, 40). Ler is a transcriptional regulator encoded within the *LEE1* operon, and it positively regulates most of the LEE operons (29). In addition, it positively and negatively regulates numerous non-LEE virulence genes, as well as housekeeping genes (1, 13, 26). Thus, Ler coordinates the expression of a large portion of the EHEC/EPEC virulon.

E. coli can use distinct pathways for polysaccharide export and capsule assembly, classified as group 1 to 4 capsules (50). The genes required for group 4 capsule (G4C) formation are

* Corresponding author. Mailing address: Department of Molecular Genetics and Biotechnology, Faculty of Medicine, The Hebrew University, POB 12272, Jerusalem 91120, Israel. Phone: 972-2-6758754. Fax: 972-2-6757308. E-mail: ilanr@ekmd.huji.ac.il.

† Supplemental material for this article may be found at <http://jb.asm.org/>.

‡ Present address: Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brazil, 1500, cep 05503-900, São Paulo, Brazil.

∇ Published ahead of print on 23 May 2008.




FIG. 1. Model of G4C, O-antigen, and capsule formation and expected phenotypes of *etk*, *etp*, and *wzy* mutants. (A) Steps in Wzy-dependent LPS O side chain and O-antigen capsule biogenesis. In step 1, the repeat units, composed of three to five sugar residues, are synthesized in the cytoplasm and then translocated to the periplasm. This step is mediated by a large number of proteins encoded mostly in the WRS locus. Steps 2a and 2b are alternative steps. In the first, the periplasmic repeat units are polymerized by Wzy into short polymers (15 to 20 repeat units), which are then ligated to the LPS core to form O side chains. In step 2b, the repeat units are polymerized, again by Wzy, into long polymers (>100 repeat units), which are then translocated to the bacterial surface to form capsules. Etp and Etk are specifically required for step 2b, whereas Wzy is required for both 2a and 2b. The 2a and 2b pathways compete for the same O repeat units. (B) Expected phenotypes upon inactivation of *etp*, *etk*, and *wzy*. (Phenotype 1) Wild-type EHEC can form both LPS O side chains (thick black broken line) and O-antigen capsules (gray zone around the bacteria), both indicated by arrows. (Phenotype 2) Mutants deficient in repeat unit synthesis or polymerization (*wzy* mutant), are expected to lack both LPS O side chains and O capsules (the thin dotted line represents the smooth outer membranes). (Phenotype 3) *etk* or *etp* mutants are expected to be deficient in O-capsule formation but to exhibit enhanced LPS O side chain formation (represented by the thick black broken line) since pathway 2b is no longer competing with pathway 2a (panel A) (32).

organized into two loci; one of these loci is indistinguishable from those responsible for the expression of many different Wzy-dependent O antigens (2, 47, 48). Moreover, this locus frequently determines both the K and O serotypes (examples include O26, O55, O100, O111, O113, and O127) (17, 32, 33), and therefore, these G4Cs have also been termed “O-antigen capsules” (17). In these cases, both the lipopolysaccharide (LPS) O antigen (also known as K_{LPS}) and the capsule (K antigen) are composed of the same repeat units, which consist of a sequence of three to five sugar residues. The genes in this locus, the Wzy-dependent repeat unit synthesis (WRS) locus, are required for the synthesis of the repeat unit, its delivery to the periplasm, and its polymerization by Wzy into both O antigen and G4C polysaccharide (G4C-PS) (Fig. 1A). Accordingly, mutants deficient in the WRS locus genes, including *wzy*, are expected to be both rough and uncapsulated (Fig. 1A and B).

The second locus that is involved in G4C formation is the G4C (*gfc*) operon, also termed the “22-minute locus” because it is mapped to min 22 in the *E. coli* K-12 genetic map (50). This operon encodes seven proteins, including Etp and Etk, that are required for repeat unit polymerization into G4C-PS and for capsule assembly (Fig. 1A) (32). Interestingly, mutants deficient in G4C formation exhibit enhanced production of O antigen (17, 32), possibly because in these mutants all of the O repeat units produced are used for O-antigen production (Fig. 1B).

In this report, we demonstrate that, like EPEC O127, EHEC O157 also forms an O antigen, G4C, and that inactivation of *etk* or *etp* renders the bacteria noncapsulated. We also show that the capsules hinder EPEC and EHEC attachment to cultured epithelial cells and inhibit actin pedestal formation,

probably via masking of the TTSS and intimin and thus attenuating Tir translocation and the intimin-Tir interaction. Interestingly, the transcription of the *gfc* operon is repressed by Ler, indicating that the expression of the TTSS by the G4C is inversely controlled by this virulence regulator. Furthermore, by using the infant rabbit model, we found that the EHEC capsule is required for efficient intestinal colonization. Taken together, our findings suggest that both EPEC and EHEC form a G4C and that temporal expression of this capsule improves the capacity of EHEC, and perhaps also EPEC, to colonize the host intestine.

MATERIALS AND METHODS

Bacterial strains, plasmids, and primers. The bacterial strains and plasmids used in this study are described in Table 1. For descriptions of the primers used, see Table S2 in the supplemental material.

Growth and infection conditions. Bacteria were grown in Luria-Bertani (LB) broth without shaking at 37°C unless stated otherwise. Where appropriate, media were supplemented with ampicillin (100 $\mu\text{g ml}^{-1}$), chloramphenicol (25 $\mu\text{g ml}^{-1}$), or kanamycin (50 $\mu\text{g ml}^{-1}$). When indicated, 0.1 mM IPTG (isopropyl- β -D-thiogalactopyranoside) was added to bacterial cultures containing expression vectors carrying *lacI^q*. The cell lines HeLa, Hep2, and Caco2 were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, 100 U ml^{-1} penicillin, and 0.1 mg ml^{-1} streptomycin at 37°C in 5% CO_2 . Before infection, the cells were washed with phosphate-buffered saline (PBS) to remove antibiotics.

Strain construction. To generate isogenic strains, we amplified DNA fragments containing tagged mutations (*etp*::*Cm*, *etk*::*kan*, and *escN*::*kan* from EPEC O127 and *wzy*::*mini-Tn5kan2* from EHEC O157 Sakai) (Table 1) and electroporated them into EDL933-containing pKD46 (10). Mutants were selected, pKD46 was eliminated, and mutations were then verified by PCR analysis and sequenced as previously described (10). For the primers used, see Table S2 in the supplemental material.

Plasmid construction. To construct pKB3105, a DNA fragment containing *tir* was amplified with primers #486 and #488 and an EDL933 DNA template. The

TABLE 1. Bacterial strains and plasmids used in this study

Strain or plasmid ^a	Description	Source or reference
Strains		
E2348/69	Wild-type EPEC O127:H6	
O1899	E2348/69 <i>etk::kan</i>	32
EDL933 Nal ^r (2280)	Nal ^r derivative of EDL933	11
SK2472	<i>etk::kan</i> mutant derivative of EDL933 Nal ^r	This study
TUV93-0 (1280)	Δ <i>stx1</i> Δ <i>stx2</i> mutant derivative of EDL933	John Leong
DF1291	TUV93-0 Δ <i>ler::kan</i>	26
SK2235	TUV93-0 Δ <i>etp::cm</i>	This study
SK1416	TUV93-0 <i>etk::kan</i>	This study
B12-D5 (1853)	EHEC O157 Saki	41
SK2526	TUV93-0 <i>wzy::mini-Tn5kan2</i> , taken from B12-D5	This study
CVD452 (63)	EPEC Δ <i>escN::kan</i>	21
SK2131	TUV93-0 Δ <i>escN::kan</i> , taken from CVD425	This study
Plasmids		
pKD46	Helper plasmid for gene deletion	10
pKD3	Template for <i>kan</i> cassette amplification	10
pCX341	Vector for <i>blaM</i> fusion formation	30
pCX392	pCX341 expressing <i>tir</i> _(EPEC) - <i>blaM</i>	This study
pKB3105	pCX341 expressing <i>tir</i> _(EHEC) - <i>blaM</i>	This study
pOI277	pACYC184 expressing <i>etk</i>	20
pAP2064	pSA10 expressing <i>etp</i>	32
pTU12 (881)	Plasmid expressing <i>ler</i>	6
pIR1 (501)	Vector for formation of <i>gfp</i> transcriptional fusions	14
pGY3159	P _{LEE1(EHEC)} - <i>gfp-mut3</i>	This study

^a In parentheses are the serial numbers in our strain collection.

amplified fragment was digested with EcoRI and KpnI and cloned into pCX341 digested with the same enzymes to generate a gene encoding a Tir-BlaM fusion protein. To construct pGY3159, a DNA fragment containing P_{LEE1} and *ler* was amplified with primers LEE1reg-F and Pler1-R and an EDL933 DNA template. The amplified fragment was digested with XbaI and BamHI and cloned into pIR1 digested with the same enzymes. For the primers used, see Table S2 in the supplemental material.

Electron microscopy. Bacteria grown overnight in LB at 37°C were washed with 0.1 M cacodylate buffer (pH 7.0), labeled with cationized ferritin (2 mg/ml; Sigma) for 30 min, and finally fixed with 5% glutaraldehyde for 1 h at room temperature (24). Fixed samples were washed, postfixed with 1% osmium tetroxide for 2 h at room temperature, dehydrated in a graded series of ethanol solutions, and then embedded in Epon resin. Thin sections were stained with 2% uranyl acetate and lead citrate and examined under a JEOL 1200EX transmission electron microscope operating at 80 kV.

Preparation of total cellular polysaccharide and separation of capsule polysaccharide from LPS. Total bacterial polysaccharides were extracted as previously described (32). Briefly, bacteria were grown overnight in 50 ml LB, the optical density (OD) of the cultures was adjusted to 1.0, and finally the cultures were centrifuged and resuspended in 500 μ l of PBS. An equal volume of saturated phenol (pH 8.0) was added, and the mixture was incubated for 30 min at 70°C with occasional mixing, followed by centrifugation (1 h, 10,000 \times g). The top, aqueous phase was recovered, 2 volumes of 100% ethanol was added to each sample, and the polysaccharides were allowed to precipitate for 1 h at -70°C. Next, the samples were centrifuged at 12,000 \times g for 30 min, after which the pellets were washed with 500 μ l of 70% ethanol, recentrifuged, and lyophilized. To separate capsule polysaccharide from LPS, the lyophilized total polysaccharide preparations were resuspended in 500 μ l of water. LPS, which formed micelles, was precipitated by ultracentrifugation (1 h, 86,000 \times g) (33). The supernatant containing the capsule polysaccharide was recovered, and residual LPS contamination was removed by phase partition with Triton X-114 as previ-

ously described (27). Briefly, Triton X-114 was added to the supernatant to a final concentration of 1%. The mixture was incubated at 4°C for 1 h with constant stirring to ensure a homogeneous solution. The mixture was then transferred to a 37°C water bath, incubated for 10 min to ensure phase partition, and centrifuged (1 h, 1,000 \times g) at 25°C. The resulting aqueous phase, containing purified capsule polysaccharide, was carefully aspirated and lyophilized. If necessary, phase partition with Triton X-114 was repeated until the preparation was LPS free, as determined by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis with anti-O157.

Analysis of LPS and capsule polysaccharide. Total cell polysaccharide was separated on 10% polyacrylamide gels containing 0.5% SDS (SDS-PAGE), and the gels were used for immunoblot analysis. SDS-PAGE analysis allowed visualization of the LPS without the interference of capsular polysaccharide, which cannot enter the gel because of its low net charge and high molecular weight (16, 33). For G4C-PS analysis by dot blotting, equivalent amounts of samples containing purified, LPS-free G4C-PS were applied directly to nitrocellulose membranes, allowed to dry, and then developed by immunoblotting with anti-O157 rabbit antisera (Statens Serum Institut, Copenhagen, Denmark) and secondary anti-rabbit immunoglobulin G conjugated to alkaline phosphatase (Sigma).

Evaluation of bacterial adhesion to epithelial cells and actin pedestal formation. Adhesion was quantified as previously described (41). Briefly, epithelial cells grown on coverslips to 80% confluence were infected with 10 μ l of overnight EHEC cultures ($\sim 10^6$ bacteria). At different time points postinfection, the monolayers were washed, fixed, treated for 2 min with 0.1% Triton X-100, and then stained with phalloidin-rhodamine. Coverslips were then washed and mounted on slides for immunofluorescence microscopy. Bacterial clusters on tissue culture cells consisting of eight or more bacteria were considered microcolonies, and the percentage of cells associated with microcolonies was determined. The numbers of microcolonies were scored as the sum of 10 microscopic fields unless otherwise stated. The efficiency of actin pedestal formation was measured as the fraction of attached bacteria forming phalloidin-labeled pedestals out of the total number of attached bacteria.

Attachment of EHEC to red blood cells (RBC). Immobilized monolayer RBC were infected, fixed, and stained as previously described (39).

Determination of the efficiency of Tir translocation by EPEC. Translocation assay by EPEC was carried out as previously described (30), with some modification. Briefly, HeLa cells seeded in 96-well plates were loaded with CCF2 (Invitrogen) for 1 h and then washed with CDMEM (CDMEM is a low-autofluorescing tissue culture medium [6, 30]) containing 2.5 mM probenecid (Sigma). The cells were then infected with overnight cultures diluted 1:50 in CCF2 loading buffer (each well was infected with 196 μ l of a solution containing 186.6 μ l CDMEM, 1 μ M CCF2, 1.8 μ l solution B, 2.7 μ l solution C, 2.5 mM probenecid, 0.1 μ M β -lactamase-inhibitory protein, and 4 μ l overnight bacterial culture (solutions B and C are from the CCF2 loading kit [Invitrogen])). Infection was carried out in a prewarmed plate reader (set at 37°C), and the rate of CCF2 hydrolysis was measured at 5-min intervals as previously described (30). For each of the strains tested, we infected six wells with cultures generated from six different colonies and calculated the average rate of CCF2 production as previously described (30). The strains used include EPEC, an *etk* mutant containing the plasmids expressing *tir-blaM* from the *tac* promoter, and a complemented strain (*etk* mutant O1899) containing plasmids pOI277 and pCX392, expressing *etk* and *tir-blaM*, respectively. The basal expression of *tir-blaM* was used in these experiments (IPTG was not added, and the infection medium included glucose). As a negative control, we infected cells with EPEC *etk::kan*, containing pCX341, expressing unfused BlaM (30).

Determination of the efficiency of Tir translocation by EHEC. For EHEC, we could not infect preloaded cells and detect translocation in real time as was done for EPEC. This is because the infection with EHEC is much slower and levels of CCF2 leakage from the cells become significant, distorting the results (our unpublished results). We therefore used endpoint measurements. EHEC bacteria containing a plasmid expressing *tir-blaM* (pKB3105) were grown overnight in LB, diluted 1:50 in CDMEM, and used to infect HeLa cells seeded in 96-well plates. At different time points postinfection, the wells were washed, overlaid with 20 μ l CCF2 loading solution, and placed in a prewarmed plate reader (30°C). Per well, the loading solution contained 2 μ M CCF2, 1.62 μ l solution B, 1.6 μ l solution C (solutions B and C were from the Invitrogen CCF2 loading kit), 2.5 mM probenecid, and 25 μ g/ml chloramphenicol in CDMEC, for a final volume of 20 μ l. Chloramphenicol was added to stop effector synthesis and translocation. The rate of CCF2 hydrolysis by BlaM (β -lactamase activity) was monitored for 30 min at 2.5-min intervals as previously described (30). We found that CCF2 reached a maximal intracellular concentration within 10 min (data not shown), and thus, for each time point, the rate of BlaM activity from 10 to 20 min postaddition of CCF2 was determined. This rate directly correlates with the

Tir-BlaM concentrations in the HeLa cells. As a negative control, we infected cells with the EHEC *etk::kan* mutant containing pX341, which expresses unfused *blaM*.

Activity of the *LEE1* promoter. To measure *LEE1* promoter activity, strains (wild-type EPEC and *etp* and *etk* mutants) containing pGY3159 were grown under repressive conditions [overnight at 30°C in LB supplemented with 20 mM (NH₄)₂SO₄]. To activate P_{*LEE1*}, cultures were washed, diluted 1:50 in CDMEM, and grown at 37°C in 96-well plates inside a microplate reader preset at 37°C (SPECTRAFluor Plus; TECAN). The fluorescence intensity (filter set at a 485-nm excitation wavelength and a 535-nm emission wavelength) and OD at 600 nm (OD₆₀₀) were read at 5-min intervals during growth. Data were collected with the Magellan version 5.0 software (TECAN).

Analysis of expressed proteins. Strains were grown as indicated, pelleted by centrifugation (5 min, 5,000 × *g*), lysed in 40 μl 2.5× SDS loading buffer (10 min, 100°C), and centrifuged for 2 min at 12,000 × *g*. Supernatant was loaded onto 12% SDS-PAGE gels and then subjected to immunoblotting with specific antibodies as indicated. Blots were developed with a secondary antibody conjugated to alkaline phosphatase or horseradish peroxidase (Sigma).

RNA analysis. Primer extension assays were carried out as described previously (12). Briefly, bacterial cultures grown to an OD₆₀₀ of 1.0 were pelleted and resuspended in 10 mM Tris (pH 7.5)–1 mM EDTA. Lysozyme was added to 0.9 mg/ml, and the samples were subjected to three freeze-thaw cycles. Total RNA was isolated with an Ultraspec RNA kit according to the manufacturer's (BIOTECH Laboratories) instructions, except that 1 ml of reagent was used for cells with an OD₆₀₀ of 12 to 16 U. The RNA samples (3 μg) were subjected to primer extension at 42°C for 45 min with avian myeloblastosis virus reverse transcriptase (CHIMWEx) and end-labeled primer 828 (GATTGCAGAAAGCTTGTG). The extension products and the sequencing reaction mixtures primed with end-labeled primer 828 were separated on a 6% sequencing gel.

Protein-DNA binding assay. A modified enzyme-linked DNA-protein interaction assay (5) was used to measure protein-DNA binding. Briefly, three DNA fragments labeled at one end with biotin were generated by PCR. These included (i) the *gfc* regulatory region (with primers BioYmcDreg-F and YmcDreg-R), (ii) the *LEE2* regulatory region (with primers BioLEE2reg2-F and 31R) as a positive control, and (iii) the *etk* coding region (with primers BioYccC-F and YccC-R) as a negative control. One hundred microliters of each of these fragments (500 pmol/ml) in PT buffer (PBS supplemented with 0.05% Tween 20 and 1 mM EDTA) was bound separately to streptavidin-coated 96-well plates (Sigma) by incubation for 1 h. Unbound DNA was removed by washing with PT. One hundred microliters of purified Ler-6His, at different concentrations in binding buffer (50 mM Tris [pH 7.4], 70 mM KCl, 5 mM EDTA, 1 mM dithiothreitol, 6% glycerol), was added to the fragment-bound wells for 1 h of incubation, and then unbound proteins were removed by washing with PT buffer. One hundred microliters of polyclonal anti-Ler antibodies was added, the wells were incubated for 1 h and washed with PT buffer, and then 100 μl of alkaline phosphatase-conjugated secondary anti-rabbit immunoglobulin G antibodies (Sigma) was added and the mixture was incubated for 1 h. The wells were washed with PT buffer and later with AP buffer (1 M Tris [pH 9.5], 0.5 mM MgCl₂). Finally, 100 μl of AP buffer containing 10 mg/ml *p*-nitrophenylphosphate was added to each well and the plate was immediately inserted into a microplate reader (SPECTRAFluor Plus; TECAN). The OD₄₀₅ was read every minute, and data were collected by the Magellan version 5.0 software (TECAN). The OD₄₀₅ values were plotted against time, and the slopes of the linear parts of these plots were calculated, representing the level of binding. One hundred percent binding was set as the binding of the highest concentration of Ler (5 μM); higher concentrations gave similar results as the system was saturated.

Infection model. Coinfection experiments with infant rabbits were performed as described previously (19). Briefly, 3-day-old infant rabbits were orogastrically inoculated with approximately equal numbers of wild-type and *etk* mutant cells at a dose equivalent to 5 × 10⁸ CFU/90 g rabbit weight. At days 2 and 7 postinfection, infected rabbits were euthanized and their intestines were removed for bacterial enumeration. Tissue homogenates were plated onto sorbitol MacConkey plates to detect both EHEC strains and then replica plated onto sorbitol MacConkey plates containing kanamycin (50 μg ml⁻¹) to enumerate the *etk* mutant cells. The data are expressed as a competitive index (CI) that represents the ratio of the number of *etk* to wild-type CFU postinfection to the number of *etk* to wild-type CFU present in the original inoculum. CI values were compared to a theoretical value of 1 (representing equal colonization of wild-type and mutant strains) by using the Wilcoxon signed rank test. Coinfection assays were performed with rabbits from two litters.

RESULTS

EPEC *etk::kan* mutant exhibits accelerated formation of actin pedestals.

We have previously shown that EPEC forms a G4C and that Etk expression is essential for its formation (32). To investigate whether the capsule plays a role in EPEC-host cell interaction, we infected HeLa cells with different EPEC strains and compared the capacities of the bacteria to attach to the cells and to form actin pedestals. Bacteria were grown as static cultures in LB for 16 h, diluted 1:50 in DMEM, and then used to infect HeLa cells. At early time points (60 and 90 min) postinfection, we found that the *etk::kan* mutant exhibits better attachment efficiency and increased formation of actin pedestals (Fig. 2A, B, and C). Moreover, the *etk* mutant exhibits increased invasiveness at early time points postinfection (Fig. 2D). However, at 3 h postinfection, we could not discern any differences in attachment, pedestal formation, or invasiveness between the *etk::kan* mutant and wild-type strains (data not shown). Complementing the *etk* mutant with a plasmid expressing Etk restored the wild-type-like slower invasiveness, attachment, and pedestal formation kinetics (Fig. 2A, B, C, and D). Similar results were obtained when we used, instead of the *etk* mutant, *etp* mutants (data not shown). These results indicate that, at early time points postinfection, the G4C might inhibit EPEC attachment and actin pedestal formation.

EPEC *etk::kan* mutant exhibits increased Tir translocation.

The formation of actin pedestals by EPEC is dependent on the delivery of Tir into the host cell membrane, followed by Tir-intimin interaction. The enhanced actin pedestal formation by the *etk* mutant might indicate that the expression of *tir*, *eae*, or the TTSS is derepressed in the *etk* mutant. However, by Western blot analysis, we found that this is not the case; wild-type EPEC and the *etk::kan* mutant express similar levels of Tir, intimin, and the TTSS components EspB, EspA, and EscJ (data not shown), indicating that the expression of *etk* or G4C formation does not affect *tir* or *eae* at the transcriptional or translational level.

An alternative explanation for the inhibitory effect of the capsule is that it masks the TTSS and/or intimin. The former should result in attenuation not only of pedestal formation but also of Tir translocation into the host cells. To test this possibility, we introduced into the three EPEC strains (the wild type, the *etk::kan* mutant, and the mutant complemented with an *etk*-expressing plasmid) a plasmid expressing *tir* fused to the *blaM* translocation reporter gene (pCX392). We then compared the efficiency of Tir translocation by these strains by using a real-time, high-resolution translocation assay (30). The results showed that initial Tir translocation by the *etk* mutant was detected as early as ~80 min postinfection, whereas Tir translocation by wild-type EPEC was detected only 40 min later, at ~120 min postinfection (Fig. 2E). Also, the efficiency of translocation by the *etk* mutant was better, as indicated by the steeper slope of the curve of product accumulation (Fig. 2E). The complemented strain translocated Tir like the wild-type strain, with lower efficiency and delayed kinetics (Fig. 2E). As a control, we confirmed that the three strains express similar levels of Tir-BlaM (data not shown). These results indicate that the G4C attenuates the EPEC TTSS activity, most likely by partial masking of the needle complex. Taken together, our results suggest that in wild-type EPEC the G4C might mask the




FIG. 2. The G4C interferes with EPEC interaction with host cells at early time points postinfection. HeLa cells were infected with overnight cultures (multiplicity of infection, ~2) of wild-type (wt) or *etk::kan* mutant EPEC or with the mutant complemented with an Etk-expressing plasmid (*etk::kan/etk*). At different time points postinfection, cells were washed, fixed, and stained with phalloidin-rhodamine, and the attachment (A) and pedestal formation (B) levels were determined. Bacterial adhesion was evaluated as the percentage of cells with eight or more bacteria attached out of the total number of cells in the microscopic field. The mean percentages and standard deviations of 10 random microscopic fields (~200 cells) are shown. The efficiency of actin pedestal formation was evaluated as the fraction of attached bacteria forming pedestals out of the total number of attached bacteria, and the mean percentages and standard deviations of five random microscopic fields (~120 HeLa cells) are shown. Typical phase-contrast and corresponding actin-stained (red) images taken at 60 min postinfection are shown in panel C. The black arrows indicate bacteria, and the yellow arrows indicate actin pedestals. In a different experiment, cells were infected with similar overnight cultures and the invasiveness of the different strains at early time points postinfection was compared by using the gentamicin protection assay (D). The assay was carried out in triplicate as previously described (4), and standard deviations are shown by bars. In panel E, the same mutants, supplemented with the reporter *tir*_{EPEC-*blaM*} gene, were used to infect HeLa cells preloaded with CCF2. The kinetics of translocation by the three mutants were determined in parallel and in real time as previously described (30). Each time point represents the average translocation by six different colonies, and the bars indicate standard errors.

TTSS and intimin, which is smaller than the TTSS in size. The TTSS masking is presumably the cause of the delayed and attenuated Tir translocation, and the intimin masking is likely to further contribute to reduced pedestal formation by hindering Tir-intimin interaction.

EHEC O157:H7 forms a G4C. We next wished to examine whether the G4C also inhibits attachment and pedestal formation in the case of EHEC O157. We previously reported that EHEC expresses Etk (20), but whether it forms a G4C was not tested. Therefore, we first examined whether EHEC produces visible capsule structures. To this end, we constructed EHEC mutated in *etk*, *etp*, and *wzy* and subjected the different strains, as well as wild-type EHEC, to electron microscopy analysis as previously described (32). The results show that whereas wild-type EHEC is coated by capsule-like material, the *etp*, *etk*, and *wzy* mutants were not capsulated (Fig. 3A). The capsule reap-

peared upon complementation of the *etk* and *etp* mutants with plasmids expressing the corresponding wild-type genes (Fig. 3A). We did not attempt to complement the *wzy* mutant, as Wzy was already reported to be required for G4C formation in other *E. coli* serotypes (2, 47, 48). These results indicate that EHEC produces a capsule that is dependent on Etk, Etp, and Wzy. To corroborate these results, we extracted the total polysaccharides from the bacteria and separated the G4C-PS from the LPS by differential ultracentrifugation and phase partition as described in Materials and Methods. We then evaluated the amounts of LPS-free G4C-PS and the LPS O side chain (O-PS) by dot blotting and Western blotting, respectively (Fig. 3B). As predicted, we found that wild-type EHEC and a TTSS mutant (*escN::kan*) produced both G4C-PS and O-PS (Fig. 3B). The *wzy* mutant produced neither G4C-PS nor O-PS (Fig. 3B), confirming previous reports that Wzy is required for G4C




FIG. 3. EHEC O157 produces an O-antigen G4C. Different EHEC strains were grown overnight in LB at 30°C and processed for electron microscopy as previously described (32). Representative ferritin-stained thin sections are shown in panel A. The strains tested include wild-type (wt) EPEC; *wzy*, *etk*, and *etp* mutants; and complemented mutants, as indicated above each frame. In panel B, total polysaccharides of EHEC were extracted and the G4C-PS was separated from the LPS as described in Materials and Methods. LPS O-antigen levels were analyzed by SDS-PAGE and Western blotting with anti-O157 antibody (B, upper panel, O-PS). Aliquots of the LPS-free G4C-PS preparation (10 μ l) were spotted onto a membrane and dried, and the amount of G4C-PS was estimated by dot blotting with anti-O157 antiserum (B, lower panel). Care was taken to apply equivalent amounts of material derived from the same numbers of bacteria to all of the lanes and spots. The genotypes of the strains analyzed are indicated above the lanes.

formation (2, 47, 48). Notably, the *etp* mutant did not produce G4C-PS but exhibited increased O-PS production (Fig. 3B). Similar results were obtained with the *etk* mutants instead of the *etp* mutant (data not shown). Introduction of a complementing plasmid into the *etp* mutant restored G4C-PS production, which was associated with reduced O-PS synthesis (Fig. 3B). We did not attempt to complement the *wzy* mutant, as Wzy was already reported to be required for G4C formation in other *E. coli* serotypes (2, 47, 48). These results indicate that EHEC O157 strain EDL933 produces an O antigen, G4C, and confirmed that (i) Etp and Etk are required for the formation of this capsule and (ii) Wzy is required for the production of both G4C-PS and O-PS. These conclusions were further supported by results from an agglutination assay and a Percoll buoyancy assay, which were carried out as previously described (32) (data not shown).

G4C-deficient EHEC exhibits increased TTSS-dependent adherence and actin pedestal formation. Previous reports indicated that EHEC rough mutants, including a *wzy* mutant, display increased binding to tissue culture cells (7, 9, 41, 42). According to these researchers' interpretations of their findings, smooth LPS interferes with EHEC attachment. Our results, however, provide an alternative interpretation of these reported results, since the rough mutants should also be G4C deficient (Fig. 1 and 3). Therefore, it appears that the smooth LPS, the G4C, or both inhibit EHEC attachment to cultured monolayers. To differentiate among these possibilities, we infected Hep2 cells with wild-type EHEC or *etp* and *wzy* mutants and analyzed the kinetics of attachment and the formation of actin pedestals. We confirmed that, as previously reported by Tatsuno et al. (41), the *wzy* mutant attached to the cells and formed actin pedestals at an increased rate (Fig. 4A and B). Importantly, the *etp* mutants exhibited similarly increased rates of attachment and actin pedestal formation (Fig. 4A and B). The differences in attachment and pedestal formation between wild-type EHEC and the mutants were most prominent at 3 to 4 h postinfection but diminished at 5 to 6 h postinfection (Fig. 4A and B). Similar results were obtained when the *etk* mutant was used instead of the *etp* mutant (data not shown). Complementing the *etp* mutant with a plasmid expressing Etp restored the slower wild-type attachment kinetics (Fig. 4A and B). Similarly, increased attachment to host cells by the *wzy*, *etk*, and *etp* mutants was observed with other cell lines, including HeLa and Caco2 (data not shown). Given that the *etp* mutant is deficient in G4C formation but efficiently forms smooth LPS (Fig. 3B), we concluded that EHEC attachment to host cells is attenuated by the G4C and not by the smooth LPS.

The major EHEC attachment mechanism involves the binding of intimin to translocated Tir, but TTSS-independent attachment mechanisms have also been reported (28, 42). However, EHEC attachment to RBC is exclusively TTSS dependent and mediated either by the EspA filament or by Tir-intimin interaction (39). To clarify whether the G4C interferes with TTSS-dependent attachment, we tested the adherence of different EHEC strains to immobilized RBC monolayers as previously described (39). We found that the absence of the G4C was associated with increased bacterial attachment to RBC (Fig. 4C), supporting the notion that the G4C interferes with TTSS-dependent cell attachment.

G4C-deficient mutants express normal levels of TTSS components but display increased translocation efficiency. We tested the possibility that increased attachment and pedestal formation by the EHEC G4C mutants is due to enhanced expression of the TTSS genes. Ler, encoded in the *LEE1* operon, is a positive regulator of *tir*, *eae*, and most of the TTSS genes. We therefore used the *gfp* reporter gene to compare the activities of the EHEC *LEE1* promoter in the different mutants. We found that wild-type EHEC and the *etp* and *etk* mutants exhibited very similar growth rates and *LEE1* expression levels (Fig. 4D and data not shown), suggesting that the inactivation of *etp* or *etk* is not associated with increased expression of *ler* and other LEE genes. This conclusion was corroborated by Western blot analysis with antibodies raised against the LEE-encoded proteins EscJ, EspA, EspB, and intimin (data not shown). Thus, as in the case of EPEC, the increased attachment and pedestal formation by the G4C




FIG. 4. The G4C interferes with EHEC interaction with host cells at early time points postinfection. (A and B) The efficiency of adherence (A) and of pedestal formation (B) by wild-type (wt) EHEC was compared to that of G4C-deficient *etp* and *wzy* mutants. Hep2 cells were infected with overnight cultures (OD, ~1.0; multiplicity of infection, ~2) of wild-type EHEC, the *wzy::Tn5* and *etp::Cm* mutants, and the complemented *etp::Cm/etp* mutant. At different time points postinfection, the cells were fixed and the actin cytoskeleton was stained with rhodamine-phalloidin. The slides were analyzed by microscopy and scored for the percentage of Hep2 cells associated with more than eight attached bacteria (A, percent attachment) and for the percentage of Hep2 cells associated with more than five pedestals (B, percent actin pedestal formation). In all cases, the standard errors obtained in the experiments were below 14% (error bars are not shown to simplify the figure). In panel A, the *wzy* graph overlaps that of *etp::Cm* and thus it is hard to see it. (C) Similarly, we also infected monolayers of immobilized RBC, as described in the text, with wild-type EHEC, the *etk::kan* mutant, and a complemented mutant (*etk::kan/etk*). At 4 h postinfection, the infected RBC were fixed and stained (bacteria and RBC are in red, and EspA filaments are in green). The images shown were taken from a representative experiment out of two, and in both cases, the attachment of the *etk* mutant was increased by ~6-fold in comparison to wild-type EHEC and by ~14-fold in comparison to the complemented *etk* mutant (data not shown). (D) Activity of the *LEE1* promoter in *etp* and *etk* mutants. A plasmid containing a *gfp* gene transcriptionally fused to the *LEE1* regulatory region (pGY3159) was introduced into wild-type EHEC and the *etp* and *etk* mutants. Overnight bacterial cultures were diluted 1:50 in CDMEM in 96-well plates, which were immediately placed in a plate reader preset at 37°C. Bacteria were grown within the plate reader under infection conditions without shaking, and growth (OD₆₀₀) and the activity of the *LEE1* promoter (fluorescence levels) were monitored at 120-s intervals. Shown is a representative experiment out of three. (E) Tir translocation by the EHEC *etk::kan* mutant. EHEC strains containing a plasmid encoding Tir_{EHEC}-BlaM (pKB3105) were used to infect HeLa cells. At 3 h (blue columns) or 3:45 h (red columns) postinfection, the cells were loaded with CCF2 and the rate of CCF2 hydrolysis in the cells, reflecting the amount of translocated Tir-BlaM, was determined as described in Materials and Methods. The genotypes of the strains used are indicated below the columns. As a negative control, we used an *etk::kan* mutant containing a plasmid expressing unfused *blaM* (pCX341). Each column represents the average translocation by six different colonies, and the bars indicate the standard errors. A representative experiment out of three is shown. Mutants were compared to the wild type by both parametric and nonparametric unpaired tests, and significant differences ($P < 0.05$) are indicated by asterisks.

EHEC mutants is not likely to be due to the increased expression of TTSS genes.

We next tested whether the G4C also inhibits Tir translocation in the case of EHEC by comparing the efficiency of Tir

translocation by wild-type EHEC to that of the *etk* mutants. As a negative control, we used a TTSS-deficient strain (*escN::kan*). Strains containing a plasmid encoding *tir-blaM* (pKB3105) were used to infect Hep2 cells, and at different time




FIG. 5. Ler represses the *gfc* promoter and G4C production. Wild-type (wt) EHEC, a *ler::kan* mutant (DF1291), and the mutant containing a plasmid containing *ler* (DF1291 containing pTU12) were grown under conditions that promote Ler expression. These strains were compared for capsule formation by electron microscopy, and representative electron micrographs of ferritin-stained thin sections are shown (A). These strains were also compared for LPS O-PS and G4C-PS production (B) and production of Ler and Etk (C). Amounts of O-PS and G4C-PS were assayed as described in the legend to Fig. 3, and the levels of Ler and Etk were assayed by Western blotting with anti-Ler or anti-Etk antibodies. To determine the *gfc* mRNA levels in these strains, equal amounts of extracted mRNA samples were subjected to a primer extension reaction and the reaction products were resolved in a 6% sequencing gel (D). Binding of Ler to the *gfc* regulatory region was tested by a modified enzyme-linked DNA-protein interaction assay as described in Materials and Methods (E). Different concentrations of purified Ler were incubated with a DNA fragment containing the *gfc* promoter region (black triangles), with negative control DNA (the *etk* coding region, black rectangles), and with positive control DNA (the *LEE2* regulatory region, open circles), and binding was quantified. One hundred percent binding was defined as the binding of the highest concentration of Ler ($5 \mu\text{M}$; higher concentrations gave similar results as the system was saturated), and the relative binding of Ler to different fragments is shown. Purified Ler tends to gradually lose activity (unpublished observation). Thus, although we used freshly purified Ler, the concentration of active Ler might be lower than that of total Ler.

points postinfection, the translocation level was determined (the assay was different from that used for EPEC, as described in Materials and Methods). The results show a significant, but not dramatic, increase in the rate of Tir-BlaM translocation by *etk* mutants (Fig. 4E). In contrast to the results obtained with EPEC, complementation of the mutant with the *etk*-expressing plasmid did not restore the reduced translocation (Fig. 4E). Interestingly, a similar increase in Tir translocation was seen when we used the *etp* mutant instead of the *etk* mutant (data not shown), but also in this case, for unknown reasons, we could not reverse the phenotype by complementation (data not shown). Possible reasons for failing to complement *etp* and *etk* mutants in this assay will be discussed later. Nevertheless, taken together, our results indicate that in both EPEC and EHEC, the G4Cs (O127 and O157 capsules, respectively) inhibit bacterial attachment to host cells, as well as actin pedestal formation, by TTSS masking and intimin shielding, resulting in reduced Tir translocation and Tir-intimin interaction.

The TTSS and G4C are conversely regulated. We next investigated why the G4C inhibitory effect fades after prolonged infection (~ 3 h for EPEC and ~ 6 h for EHEC). A partial explanation for this apparent inconsistency might be the elongation of the EspA filament (15) to allow Tir delivery through the capsule. However, the capsule should still inhibit attachment via intimin masking and interfering with its interaction with the translocated Tir. Another scenario that can resolve

this paradox is that upregulation of TTSS assembly is associated with the downregulation of G4C formation. To test this possibility, we examined whether the EHEC *ler::kan* mutant, deficient in the expression of most of the TTSS genes, can form G4C similar to that of wild-type EHEC.

We first compared wild-type EHEC and the *ler::kan* mutant by electron microscopy and found that they appeared to be similar (Fig. 5A). However, since electron microscopy cannot be used to quantify capsular size, we could not exclude possible differences in the quantity of capsular polysaccharide between the two. Notably, a dramatic capsule disappearance was visualized upon the complementation of the *ler* mutant with a *ler*-expressing plasmid (Fig. 5A), resulting in modest *ler* overexpression (Fig. 5C). These results suggest that Ler might negatively regulate capsule production.

To further test this possibility, we extracted the total polysaccharides from wild-type EHEC and a *ler* mutant grown overnight in DMEM. The LPS and G4C-PS were then separated as previously described (see Materials and Methods). The amount of O antigen (LPS-associated O-PS) was then tested by Western blotting with anti-O157 antibody (Fig. 5B, upper panel), and the amount of capsular polysaccharide (LPS free, G4C-PS) was evaluated by dot immunoblot analysis with anti-O157 antibody (Fig. 5B, lower panel). Care was taken to apply equivalent amounts of material derived from the same numbers of bacteria in all of the lanes and spots. We found that




FIG. 6. Attenuated intestinal colonization by an EHEC *etk* mutant. Infant rabbits were coinfecting with EDL933 NaI^r and an isogenic *etk::kan* mutant (SK2472). At days 2 (A) and 7 (B) postinfection, CI values were determined. Each point represents an animal, and the bars represent the geometric mean. Open symbols represent animals in which no *etk* mutant CFU was recovered from the lowest dilution; the results were adjusted to represent the recovery of 1 CFU at that dilution. The data were compared to a theoretical CI of 1 with the Wilcoxon signed rank test, and the *P* values obtained are shown. Nonsignificant results are marked as NS.

the *ler* mutant produced more capsular polysaccharide (and less LPS-associated O antigen; Fig. 5B). Moreover, complementation of the *ler* mutant with a *ler*-expressing plasmid was associated with a dramatic reduction in capsule production (Fig. 5B, lower panel). Taken together, our findings suggest that Ler, or a product of a gene positively regulated by Ler (possibly a TTSS component), represses capsule formation.

Ler inhibits G4C formation by repressing *gfc* operon transcription. Ler positively controls the expression of TTSS and other virulence-associated genes but also represses a large number of virulence and housekeeping genes (1). We therefore tested whether Ler represses the expression of the *gfc* operon. First, we extracted proteins from EHEC grown under Ler-expressing conditions (overnight static culture in DMEM) and used Western blot analyses with anti-Etk and anti-Ler antibodies to assess the Ler and Etk levels in the bacteria. Importantly, we found that Ler expression was directly correlated with Etk downregulation (Fig. 5C). In the *ler::kan* mutant, Ler was absent and the Etk levels were elevated. In contrast, in wild-type EHEC and the complemented *ler* mutant, Ler was produced and the Etk levels were reduced (Fig. 5C). Similar inhibition of Etk production by Ler was found when we used EPEC O127 instead of EHEC (data not shown). Given that the *gfc* operon is controlled by a single promoter (32), our results suggest that Ler might repress (directly or indirectly) the *gfc* promoter.

To further test the role of Ler in the repression of the *gfc* promoter, we extracted mRNA from similarly grown EHEC strains and used it to perform primer extension analyses with a primer complementing the *ymcD* gene mRNA (32). Primer extension was performed, and the products were resolved with a sequencing gel as previously described (see Materials and Methods and reference 32). We found markedly elevated *gfc* mRNA levels in the *ler* mutant, whereas in wild-type EHEC and the complemented *ler* mutant, the *gfc* mRNA levels were reduced (Fig. 5D). These results support the hypothesis that Ler directly or indirectly represses the *gfc* promoter.

To explore whether Ler directly represses *gfc* expression, we tested the ability of Ler to bind to DNA fragments containing the *gfc* promoter region (presumably the regulatory region of this promoter). The solid-phase DNA-binding assay (5) was used to compare Ler binding to three DNA fragments, (i) a fragment containing the *gfc* regulatory region, (ii) a fragment containing the *LEE2* regulatory region (positive control), and

(iii) a fragment consisting of part of the *etk* coding region (the negative control). We found that purified Ler efficiently binds to the *gfc* regulatory region and to the positive control DNA but not to the negative control DNA (Fig. 5E), supporting the hypothesis that Ler directly represses the *gfc* promoter.

Taken together, the above results indicate that the expression of TTSS operons and that of the *gfc* operon are conversely regulated at the transcription level and that Ler might directly repress the *gfc* promoter. Thus, these results explain why the inhibition of attachment by the G4C is temporary.

The G4C is required for efficient colonization of the infant rabbit intestine. We next investigated how the G4C might contribute to bacterial fitness. One possibility is that the G4C contributes to *E. coli* fitness in the environment. Another possibility is that transient capsule expression contributes to host colonization. To test the latter possibility, we tested how a G4C deficiency would influence EHEC colonization of the host intestine in the infant rabbit model (35). Briefly, 3-day-old infant rabbits were coinoculated with the wild type and the *etk* mutant. The numbers of wild-type and *etk* mutant CFU in different intestinal sections were determined 2 and 7 days postinoculation, and CI values were calculated. At 2 days postinoculation, the CI values were 0.007 and 0.005 in the cecum and colon (Fig. 6A), indicating that the *etk* mutant has a markedly (>150-fold) reduced capacity to colonize these regions of the intestine. The CI in the ileum was ~0.02 (Fig. 6A), but the difference did not reach statistical significance. Thus, the G4C appears to be most important for efficient colonization of regions distal to the ileum. At 7 days postinoculation, the results were very similar although the reduction in colonization by the *etk* mutant compared with the wild type was slightly less marked than that observed on day 2 (Fig. 6B). These results suggest that G4C is required for efficient colon colonization by EHEC.

DISCUSSION

Formation of G4C by EPEC and EHEC. The *gfc* operon comprises seven genes, *ymcD*, *ymcC*, *ymcB*, *ymcA*, *yccZ*, *etp*, and *etk* (20, 32, 45). In this report, we show that EHEC O157, including strains EDL933 (shown here) and Sakai (data not shown), form an O-antigen capsule whose assembly is dependent on Etp and Etk. The existence of this O-antigen capsule in EHEC O157 has been overlooked, probably because it can-

not be identified by standard serological tests. We did not test the involvement of the other *gfc* genes in G4C assembly by EHEC, but it is likely that, as in EPEC O127 (32), the products of these genes are also required for G4C assembly in EPEC O157. Given their role in G4C formation, we suggest that *ymcD*, *ymcC*, *ymcB*, *ymcA*, and *yccZ* be renamed *gfcA*, *gfcB*, *gfcC*, *gfcD*, and *gfcE*, respectively.

G4C inhibits the interaction of EPEC and EHEC with host cells. EHEC O157 rough mutants display increased binding to tissue culture cells (7, 9, 41, 42). On the basis of these results, it was suggested that LPS plays an inhibitory role in attachment. Our new findings suggest, however, that this is not the case and that it is the G4C that inhibits attachment. Moreover, we showed that also in EPEC the G4C inhibits attachment to host cells and the formation of actin pedestals. This inhibition is probably mediated by the masking of the TTSS and intimin to reduce both Tir translocation and intimin-Tir interaction. The inhibition of Tir translocation is only partial, perhaps because the EHEC and EPEC TTSSs are fitted with the EspA extension filament (38), allowing protein injection through the capsule. This might indicate that intimin masking plays a more dominant role in inhibition of attachment and pedestal formation than that of TTSS masking.

Masking of intimin-like adhesins and TTSS by capsule and other bacterial surface structures. The thickness of the G4C of EPEC and EHEC was not determined, but it probably resembles that of other capsules, which may typically extend 100 to 1,000 nm from the bacterial surface, depending on its type and composition (37). Masking by capsule of *E. coli* adhesins similar to intimin in size, protruding ~10 nm beyond the outer membrane (23), was previously reported by Schembri et al. (37). In fact, on the basis of their results, these authors predict that intimin might also be subjected to masking by encapsulation. This phenomenon is not restricted to *E. coli* and was also reported in other bacteria, including *Klebsiella pneumoniae* (36) and *Neisseria* (46). Shielding of TTSSs by capsule was never reported before, but two reports describe TTSS shielding by other bacterial surface structures (49). The activity of the *Yersinia* TTSS can be inhibited via masking by the surface protein YadA (31), and the activity of the *Shigella* TTSS can be masked and inhibited by the LPS O antigen (49).

Solving the shielding dilemma. The shielding concept leaves the bacteria with an obvious dilemma. They cannot translocate protein or adhere without the assistance of adhesin proteins and the TTSS, but at the same time, the shields contribute to bacterial fitness by providing protection against countermeasures at the disposal of a mammalian host. *Yersinia* solved the shielding dilemma by careful adjustment of the respective lengths of the TTSS needle and YadA, such that the length of the TTSS needle is the minimum that still allows efficient protein translocation through the YadA shield (31). In the case of *Shigella*, glucosylation of the LPS O antigen, via a bacteriophage-encoded enzyme, shortens the O antigens and thus enhances the TTSS function without compromising the protective properties of the LPS (49). Interestingly, we found that some *Shigella* strains contain an intact *gfc* operon and can express Etk (unpublished results). It remains to be seen whether *Shigella* also produces an O-antigen capsule and, if so, whether it also plays a role in TTSS masking and whether, like the LPS O antigen, it is subjected to glucosylation.

EPEC and EHEC display a dual solution to the shielding dilemma. First, the capsule only partially inhibits protein translocation, probably reflecting the capacity of these pathogens to fit the TTSS with the EspA filament, which can traverse, and inject proteins through, the capsule. Thus, it is expected that, upon the assembly of elongated EspA filaments, these bacteria can use the TTSS for protein translocation even in their capsulated form. Intimin, however, is expected to remain masked in capsulated bacteria. The second solution of EPEC/EHEC to this dilemma is to reduce the capsule size upon the expression of intimin and the TTSS. Taken together, these findings suggest that it is possible that, at some initial infection phase, the bacteria can efficiently translocate Tir and other effectors, whereas intimin is still shielded by the capsule. Thus, the rate of capsule thinning may modulate a time gap between Tir translocation and its clustering beneath the bacteria by intimin.

Inhibition of *gfc* expression by Ler. Importantly, we found that the production of the G4C and the LEE proteins (including TTSS components, Tir, and intimin) is inversely coordinated by Ler at the transcriptional level. This ensures that activation of the TTSS-related genes is associated with repression of the *gfc* promoter. Ler exhibits a general structure that is similar to that of H-NS (14, 29), and like H-NS, it appears to polymerize on the target DNA to cover stretches of ~200 bp, sometimes without clear boundaries (6, 18, 29). Its positive effect on LEE gene expression is mediated by its binding to specific regions in the LEE and thereby negating the H-NS-mediated repression (8, 18, 43, 44). This antirepressor activity is probably mediated by interfering with a specific H-NS-DNA complex (8, 18, 43). How Ler mediates the repression of the *gfc* promoter is not clear. Given that Ler binds the regulatory region of the *gfc* promoter, we speculate that Ler might interfere with the binding of the RNA polymerase to this promoter. Clearly, detailed investigation of the Ler-mediated repression of the *gfc* promoters is needed to solve the repression mechanism, but this study was outside the scope of the present work.

Role of the G4C in improving bacterial fitness. Polysaccharide capsules were implicated in protecting bacteria from desiccation and were found to be involved in virulence by protecting the bacteria from phagocytosis, complement, and bactericidal-peptide-like defensins. It is not clear, however, how the G4C contributes to the fitness of EPEC or EHEC. Previous reports show some disadvantages associated with G4C formation, which leads to the formation of LPS with less O antigen. In *E. coli* O111 and O127, this reduction in LPS O antigen is associated with hypersensitivity to complement, whereas noncapsulated mutants become complement resistant (16, 32). An additional disadvantage associated with capsule formation was found in this study, namely, interfering with the function of adhesins and TTSS. However, the fact that the bacteria maintain the capsule indicates that this surface structure contributes to bacterial fitness under some conditions. In support of this notion, by using the infant rabbit model, we found that the G4C-deficient mutant has a markedly reduced capacity to colonize the host intestine, particularly in regions distal to the ileum. These findings, together with the results presented in this report, suggest that dynamic, temporal, and spatial regulation of the production of the TTSS and the G4C is important for optimal EHEC colonization of the host intestine. However, it is not clear how the G4C promotes EHEC

colonization. Recently, Lacour and colleagues (25) showed that *etk* mutants are more sensitive to the antibacterial peptide polymyxin B, raising the possibility that the G4C protects EHEC from some antibacterial factors encountered in the host gastrointestinal tract. It is also possible that the capsule promotes initial transient attachment to the host intestinal tissue. The latter might explain why we could not restore reduced Tir translocation upon complementation (Fig. 4E) since, if this is the case, thick capsule might improve initial attachment but still inhibit translocation. In contrast, thin or patchy capsule will promote initial attachment without inhibition of translocation and thus enhance translocation. Nevertheless, we do not have any evidence to support the above hypothesis.

ACKNOWLEDGMENTS

We thank J. Leong, M. Stevens, and J. Kaper for bacterial strains and G. Frankel and B. Kenny for providing antibodies.

This work was supported by grants from the United States-Israel Binational Science Foundation, the Center of Study of Emerging Disease, the EraNet-PathoGenomic program, and the Abisch-Frenkel Foundation. T.B. was supported by a Boehringer Ingelheim Fonds scholarship, and G.Y. was supported by the Einstein Scholarship sponsored by the Isaac Kaye Foundation. M.K.W. and J.M.R. were supported by HHMI and NIH.

REFERENCES

- Abe, H., A. Miyahara, T. Oshima, K. Tashiro, Y. Ogura, S. Kuhara, N. Ogasawara, T. Hayashi, and T. Tobe. 2008. Global regulation by horizontally transferred regulators establishes the pathogenicity of *Escherichia coli*. *DNA Res.* **15**:25–38.
- Amor, P. A., and C. Whitfield. 1997. Molecular and functional analysis of genes required for expression of group IB K antigens in *Escherichia coli*: characterization of the his-region containing gene clusters for multiple cell-surface polysaccharides. *Mol. Microbiol.* **26**:145–161.
- Bell, B. P., M. Goldoft, P. M. Griffin, M. A. Davis, D. C. Gordon, P. I. Tarr, C. A. Bartleson, J. H. Lewis, T. J. Barrett, J. G. Wells, et al. 1994. A multistate outbreak of *Escherichia coli* O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. *The Washington experience*. *JAMA* **272**:1349–1353.
- Ben-Ami, G., V. Ozeri, E. Hanski, F. Hofmann, K. Aktories, K. M. Hahn, G. M. Bokoch, and I. Rosenshine. 1998. Agents that inhibit Rho, Rac, and Cdc42 do not block formation of actin pedestals in HeLa cells infected with enteropathogenic *Escherichia coli*. *Infect. Immun.* **66**:1755–1758.
- Benotmane, A. M., M. F. Hoylaerts, D. Collen, and A. Belayew. 1997. Nonisotopic quantitative analysis of protein-DNA interactions at equilibrium. *Anal. Biochem.* **250**:181–185.
- Berdichevsky, T., D. Friedberg, C. Nadler, A. Rokney, A. Oppenheim, and I. Rosenshine. 2005. Ler is a negative autoregulator of the LEE1 operon in enteropathogenic *Escherichia coli*. *J. Bacteriol.* **187**:349–357.
- Bilge, S. S., J. C. Vary, Jr., S. F. Dowell, and P. I. Tarr. 1996. Role of the *Escherichia coli* O157:H7 O side chain in adherence and analysis of an *rfb* locus. *Infect. Immun.* **64**:4795–4801.
- Bustamante, V. H., F. J. Santana, E. Calva, and J. L. Puente. 2001. Transcriptional regulation of type III secretion genes in enteropathogenic *Escherichia coli*: Ler antagonizes H-NS-dependent repression. *Mol. Microbiol.* **39**:664–678.
- Cockerill, F., III, G. Beebakhee, R. Soni, and P. Sherman. 1996. Polysaccharide side chains are not required for attaching and effacing adhesion of *Escherichia coli* O157:H7. *Infect. Immun.* **64**:3196–3200.
- Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA* **97**:6640–6645.
- Dziva, F., P. M. van Diemen, M. P. Stevens, A. J. Smith, and T. S. Wallis. 2004. Identification of *Escherichia coli* O157: H7 genes influencing colonization of the bovine gastrointestinal tract using signature-tagged mutagenesis. *Microbiology* **150**:3631–3645.
- Elgrably-Weiss, M., S. Park, E. Schlosser-Silverman, I. Rosenshine, J. Imlay, and S. Altuvia. 2002. A *Salmonella enterica* serovar Typhimurium *hemA* mutant is highly susceptible to oxidative DNA damage. *J. Bacteriol.* **184**:3774–3784.
- Elliott, S. J., V. Sperandio, J. A. Giron, S. Shin, J. L. Mellies, L. Wainwright, S. W. Hutcheson, T. K. McDaniel, and J. B. Kaper. 2000. The locus of enterocyte effacement (LEE)-encoded regulator controls expression of both LEE- and non-LEE-encoded virulence factors in enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect. Immun.* **68**:6115–6126.
- Friedberg, D., T. Umanski, Y. Fang, and I. Rosenshine. 1999. Hierarchy in the expression of the locus of enterocyte effacement genes of enteropathogenic *Escherichia coli*. *Mol. Microbiol.* **34**:941–952.
- Garmendia, J., G. Frankel, and V. F. Crepin. 2005. Enteropathogenic and enterohemorrhagic *Escherichia coli* infections: translocation, translocation, translocation. *Infect. Immun.* **73**:2573–2585.
- Goldman, R. C., K. Joiner, and L. Leive. 1984. Serum-resistant mutants of *Escherichia coli* O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen. *J. Bacteriol.* **159**:877–882.
- Goldman, R. C., D. White, F. Orskov, I. Orskov, P. D. Rick, M. S. Lewis, A. K. Bhattacharjee, and L. Leive. 1982. A surface polysaccharide of *Escherichia coli* O111 contains O-antigen and inhibits agglutination of cells by O-antiserum. *J. Bacteriol.* **151**:1210–1221.
- Haack, K. R., C. L. Robinson, K. J. Miller, J. W. Fowlkes, and J. L. Mellies. 2003. Interaction of Ler at the LEE5 (*tir*) operon of enteropathogenic *Escherichia coli*. *Infect. Immun.* **71**:384–392.
- Ho, T. D., and M. K. Waldor. 2007. Enterohemorrhagic *Escherichia coli* O157:H7 *gal* mutants are sensitive to bacteriophage P1 and defective in intestinal colonization. *Infect. Immun.* **75**:1661–1666.
- Ilan, O., Y. Bloch, G. Frankel, H. Ullrich, K. Geider, and I. Rosenshine. 1999. Protein tyrosine kinases in bacterial pathogens are associated with virulence and production of exopolysaccharide. *EMBO J.* **18**:3241–3248.
- Jarvis, K. G., J. A. Giron, A. E. Jerse, T. K. McDaniel, M. S. Donnenberg, and J. B. Kaper. 1995. Enteropathogenic *Escherichia coli* contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proc. Natl. Acad. Sci. USA* **92**:7996–8000.
- Kaper, J. B., J. P. Nataro, and H. L. Mobley. 2004. Pathogenic *Escherichia coli*. *Nat. Rev. Microbiol.* **2**:123–140.
- Kelly, G., S. Prasannan, S. Daniell, K. Fleming, G. Frankel, G. Dougan, I. Connerton, and S. Matthews. 1999. Structure of the cell-adhesion fragment of intimin from enteropathogenic *Escherichia coli*. *Nat. Struct. Biol.* **6**:313–318.
- Knutton, S., P. H. Williams, D. R. Lloyd, D. C. Candy, and A. S. McNeish. 1984. Ultrastructural study of adherence to and penetration of cultured cells by two invasive *Escherichia coli* strains isolated from infants with enteritis. *Infect. Immun.* **44**:599–608.
- Lacour, S., P. Doublet, B. Obadia, A. J. Cozzzone, and C. Grangeasse. 2006. A novel role for protein-tyrosine kinase Etk from *Escherichia coli* K-12 related to polymyxin resistance. *Res. Microbiol.* **157**:637–641.
- Li, M., I. Rosenshine, S. L. Tung, X. H. Wang, D. Friedberg, C. L. Hew, and K. Y. Leung. 2004. Comparative proteomic analysis of extracellular proteins of enterohemorrhagic and enteropathogenic *Escherichia coli* strains and their *ihf* and *ler* mutants. *Appl. Environ. Microbiol.* **70**:5274–5282.
- Liu, S., R. Tobias, S. McClure, G. Styba, Q. Shi, and G. Jackowski. 1997. Removal of endotoxin from recombinant protein preparations. *Clin. Biochem.* **30**:455–463.
- Low, A. S., F. Dziva, A. G. Torres, J. L. Martinez, T. Rosser, S. Naylor, K. Spears, N. Holden, A. Mahajan, J. Findlay, J. Sales, D. G. Smith, J. C. Low, M. P. Stevens, and D. L. Gally. 2006. Cloning, expression, and characterization of fimbrial operon F9 from enterohemorrhagic *Escherichia coli* O157:H7. *Infect. Immun.* **74**:2233–2244.
- Mellies, J. L., S. J. Elliott, V. Sperandio, M. S. Donnenberg, and J. B. Kaper. 1999. The Per regulon of enteropathogenic *Escherichia coli*: identification of a regulatory cascade and a novel transcriptional activator, the locus of enterocyte effacement (LEE)-encoded regulator (Ler). *Mol. Microbiol.* **33**:296–306.
- Mills, E., K. Baruch, X. Charpentier, S. Kobi, and I. Rosenshine. 2008. Real-time analysis of effector translocation by the type III secretion system of enteropathogenic *Escherichia coli*. *Cell Host Microbe* **3**:104–113.
- Mota, L. J., L. Journet, I. Sorg, C. Agrain, and G. R. Cornelis. 2005. Bacterial injectisomes: needle length does matter. *Science* **307**:1278.
- Peleg, A., Y. Shifrin, O. Ilan, C. Nadler-Yona, S. Nov, S. Koby, K. Baruch, S. Altuvia, M. Elgrably-Weiss, C. M. Abe, S. Knutton, M. A. Saper, and I. Rosenshine. 2005. Identification of an *Escherichia coli* operon required for formation of the O-antigen capsule. *J. Bacteriol.* **187**:5259–5266.
- Peterson, A. A., and E. J. McGroarty. 1985. High-molecular-weight components in lipopolysaccharides of *Salmonella typhimurium*, *Salmonella minnesota*, and *Escherichia coli*. *J. Bacteriol.* **162**:738–745.
- Ritchie, J. M., C. M. Thorpe, A. B. Rogers, and M. K. Waldor. 2003. Critical roles for *stx2*, *eae*, and *tir* in enterohemorrhagic *Escherichia coli*-induced diarrhea and intestinal inflammation in infant rabbits. *Infect. Immun.* **71**:7129–7139.
- Ritchie, J. M., and M. K. Waldor. 2005. The locus of enterocyte effacement-encoded effector proteins all promote enterohemorrhagic *Escherichia coli* pathogenicity in infant rabbits. *Infect. Immun.* **73**:1466–1474.
- Schembri, M. A., J. Blom, K. A. Krogløft, and P. Klemm. 2005. Capsule and fimbria interaction in *Klebsiella pneumoniae*. *Infect. Immun.* **73**:4626–4633.
- Schembri, M. A., D. Dalsgaard, and P. Klemm. 2004. Capsule shields the function of short bacterial adhesins. *J. Bacteriol.* **186**:1249–1257.
- Sekiya, K., M. Ohishi, T. Oginio, K. Tamano, C. Sasakawa, and A. Abe. 2001.

- Supermolecular structure of the enteropathogenic *Escherichia coli* type III secretion system and its direct interaction with the EspA-sheath-like structure. *Proc. Natl. Acad. Sci. USA* **98**:11638–11643.
39. **Shaw, R. K., S. Daniell, G. Frankel, and S. Knutton.** 2002. Enteropathogenic *Escherichia coli* translocate Tir and form an intimin-Tir intimate attachment to red blood cell membranes. *Microbiology* **148**:1355–1365.
 40. **Spears, K. J., A. J. Roe, and D. L. Gally.** 2006. A comparison of enteropathogenic and enterohaemorrhagic *Escherichia coli* pathogenesis. *FEMS Microbiol. Lett.* **255**:187–202.
 41. **Tatsuno, I., K. Nagano, K. Taguchi, L. Rong, H. Mori, and C. Sasakawa.** 2003. Increased adherence to Caco-2 cells caused by disruption of the *yhiE* and *yhiF* genes in enterohemorrhagic *Escherichia coli* O157:H7. *Infect. Immun.* **71**:2598–2606.
 42. **Torres, A. G., and J. B. Kaper.** 2003. Multiple elements controlling adherence of enterohemorrhagic *Escherichia coli* O157:H7 to HeLa cells. *Infect. Immun.* **71**:4985–4995.
 43. **Torres, A. G., G. N. Lopez-Sanchez, L. Milflores-Flores, S. D. Patel, M. Rojas-Lopez, C. F. Martinez de la Pena, M. M. Arenas-Hernandez, and Y. Martinez-Laguna.** 2007. Ler and H-NS, regulators controlling expression of the long polar fimbriae of *Escherichia coli* O157:H7. *J. Bacteriol.* **189**:5916–5928.
 44. **Umanski, T., I. Rosenshine, and D. Friedberg.** 2002. Thermoregulated expression of virulence genes in enteropathogenic *Escherichia coli*. *Microbiology* **148**:2735–2744.
 45. **Vincent, C., B. Duclos, C. Grangeasse, E. Vaganay, M. Riberty, A. J. Cozzone, and P. Doublet.** 2000. Relationship between exopolysaccharide production and protein-tyrosine phosphorylation in gram-negative bacteria. *J. Mol. Biol.* **304**:311–321.
 46. **Virji, M., K. Makepeace, I. R. Peak, D. J. Ferguson, M. P. Jennings, and E. R. Moxon.** 1995. Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. *Mol. Microbiol.* **18**:741–754.
 47. **Wang, L., C. E. Briggs, D. Rothmund, P. Fratamico, J. B. Luchansky, and P. R. Reeves.** 2001. Sequence of the *E. coli* O104 antigen gene cluster and identification of O104 specific genes. *Gene* **270**:231–236.
 48. **Wang, L., H. Curd, W. Qu, and P. R. Reeves.** 1998. Sequencing of *Escherichia coli* O111 O-antigen gene cluster and identification of O111-specific genes. *J. Clin. Microbiol.* **36**:3182–3187.
 49. **West, N. P., P. Sansonetti, J. Mounier, R. M. Exley, C. Parsot, S. Guadagnini, M. C. Prevost, A. Prochnicka-Chalufour, M. Delepierre, M. Tanguy, and C. M. Tang.** 2005. Optimization of virulence functions through glucosylation of *Shigella* LPS. *Science* **307**:1313–1317.
 50. **Whitfield, C.** 2006. Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annu. Rev. Biochem.* **75**:39–68.